Tucatinib (Tukysa) is an FDA-approved medication for treating HER2-positive breast cancer, specifically in cases where the cancer is metastatic or inoperable.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

The U.S. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.

The U.S. Food and Drug Administration (FDA) granted approval to Sevenfact on April 1, 2020.

The European Commission has approved Roche's OCREVUS for subcutaneous use, making it the first and only twice-yearly injection for relapsing and primary progressive multiple sclerosis.

The U.S. Food and Drug Administration (FDA) approved Ozanimod, marketed under the brand name Zeposia, on March 25, 2020.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.

The U.S. Food and Drug Administration (FDA) approved Isatuximab, under the brand name Sarclisa, on March 2, 2020. This medication is classified as a CD38 monoclonal antibody and is specifically used to treat multiple myeloma in adults.

This IND will enable the assessment of ADI-270, for the therapeutic intervention in relapsed/refractory renal cell carcinoma.

The U.S. Food and Drug Administration (FDA) approved Rimegepant, under the brand name Nurtec ODT, on February 27, 2020.

Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.